Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting (TRIVOLVE)
A Prospective Non-interventional Study in Patients With Chronic Obstructive Pulmonary Disease That Evolve to Fixed Long-acting Muscarinic Antagonist/Long-acting beta2-agonist/Inhaled Corticosteroid Triple Therapy, Trimbow®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This non-interventional study assesses the real-life effectiveness and safety of the fixed triple therapy Trimbow® compared to free triple therapy, considering patient individual data, in clinical practice at second and thirdline centres in patients with confirmed moderate to severe chronic obstructive pulmonary disease.
This is an hypothesis generating study. No formal primary endpoint is defined; parameters are evaluated in an exploratory or descriptive manner.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2020
- ZNA Middelheim
-
Antwerp, Belgium, 2650
- Universitair Ziekenhuis Antwerpen
-
Antwerp, Belgium
- GZA Campus Sint-Vincentius
-
Brussel, Belgium
- UZ Brussel
-
Brussels, Belgium
- Hopital Erasme
-
Charleroi, Belgium, 6000
- Grand Hôpital de Charleroi
-
Charleroi, Belgium
- Clinique Notre-Dame de Grâce ASBL Gosselies
-
Gent, Belgium
- UZ Gent
-
Kortrijk, Belgium
- AZ Groeninge
-
Liège, Belgium
- CHR de la Citadelle
-
Mechelen, Belgium
- AZ Sint-Maarten
-
Montigny-le-Tilleul, Belgium
- Hôpital André Vésale
-
Namur, Belgium
- Clinique Saint-Luc Bouge
-
Roeselare, Belgium
- AZ Delta
-
Tournai, Belgium
- Hospital Center De Wallonie Picarde
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient has provided written informed consent
- Patient is aged 40 years or older at time of initiation of Trimbow® treatment
- Patient is diagnosed with moderate or severe chronic obstructive pulmonary disease confirmed by spirometry (post-bronchodilation) based on the Global Initiative for chronic obstructive lung disease (GOLD) 2018 classification
- Patient treated with double inhalation or free triple therapy (using at least 2 devices) who are prescribed Trimbow®
Exclusion Criteria:
• Hypersensitivity to the active substances or to any of the excipients listed below:
- Ethanol anhydrous
- Hydrochloric acid
- Norflurane (propellant)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inhalation technique score
Time Frame: up to 6 months
|
Change in Inhalation Technique Score, measured as percentage of correct steps on the Inhalation Checklist (itemized instructions of inhaler correct use per respective Summaries of Product Characteristics) at each routine follow-up visit up to 6 months versus baseline. This is an hypothesis generating study. No formal primary endpoint is defined; parameters are evaluated in an exploratory or descriptive manner. |
up to 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment adherence score
Time Frame: up to 6 months
|
Degree of treatment adherence measured via the mean score on the Test of Adherence to Inhalers (TAI) questionnaire, including 5 questions completed by the patient (each item scored from 1 (worst) to 5 (best) with a range from 10 to 50) and 2 items completed by the physician (each item scored 1 (bad) or 2 (good) with a range from 2 to 4) at baseline and each routine follow-up visit up to 6 months versus baseline.
|
up to 6 months
|
|
Number of inhaled doses recorded by dose counter since previous visit
Time Frame: up to 6 months
|
Number of inhaled doses recorded by dose counter of the inhaler since previous visit, at the first and second routine follow-up visit.
|
up to 6 months
|
|
Patient's treatment satisfaction score using visual analogue scale (0-10)
Time Frame: up to 6 months
|
The patient's treatment satisfaction score measured on a visual analogue scale from 0 (worst) to 10 (best), at baseline and each routine follow-up visit.
|
up to 6 months
|
|
Number of rescue medication used within 7 days prior to each visit
Time Frame: up to 6 months
|
The number of rescue medication used within 7 days prior to each visit, recorded at baseline and each routine follow-up visit.
|
up to 6 months
|
|
Patient's lung function as measured by spirometry
Time Frame: up to 6 months
|
The pre and post bronchodilator forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) are measured at baseline and each routine follow-up visit.
|
up to 6 months
|
|
Symptoms score by the Chronic obstructive pulmonary disease Assessment Test (CAT) questionnaire
Time Frame: up to 6 months
|
Patients complete the 8-item CAT questionnaire at baseline and each follow-up visit.
Total scores range from 0 to 40 and higher scores indicate a worse health status.
|
up to 6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of moderate and severe exacerbations at baseline (12 months prior to start) and last follow-up visit
Time Frame: up to 6 months
|
The number of moderate and severe exacerbations that occurred within the previous year is collected at the baseline visit and the number of moderate and severe exacerbations occurring during the study is collected at the final visit.
Moderate exacerbations are defined as exacerbations that require oral corticosteroid and/or antibiotic treatment.
Severe exacerbations are defined as exacerbations that require oral corticosteroid and/or antibiotic treatment plus hospital admission.
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guy Brusselle, MD-PhD, University Ghent
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Beclomethasone
- Glycopyrrolate
- Formoterol Fumarate
Other Study ID Numbers
Other Study ID Numbers
- CHIESI_NIS_0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.